Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Ainos, Inc. - warrants (NQ: AIMDW )

0.0260 UNCHANGED
Last Price Updated: 9:30 AM EDT, Oct 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ainos, Inc. - warrants

< Previous 1 2 Next >
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Via ACCESSWIRE
Ainos Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
Via ACCESSWIRE
Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
Via ACCESSWIRE
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
Via ACCESSWIRE
Ainos Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Ainos Celebrates First Listing Anniversary on Nasdaq
Via ACCESSWIRE
Ainos Issues Mid-Year Business Update Letter to Shareholders
Via ACCESSWIRE
Ainos Provides Insights Into Its AI Nose Technology
Via ACCESSWIRE
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target
Via ACCESSWIRE
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption
Via ACCESSWIRE
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target
Via ACCESSWIRE
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales
Via ACCESSWIRE
Ainos Appoints Amanda Sung as New Chief Financial Officer
Via ACCESSWIRE
Ainos Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
Ainos Reports Fourth Quarter and Full Year 2022 Financial Results
Via ACCESSWIRE
Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan
Via ACCESSWIRE
Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug
Via ACCESSWIRE
Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients
Via ACCESSWIRE
Ainos Announces US$3 Million Convertible Notes Private Placement
Via ACCESSWIRE
Ainos Issues 2023 Shareholder Letter
Via ACCESSWIRE
Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization
Via ACCESSWIRE
Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron
Via ACCESSWIRE
Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms
Via ACCESSWIRE
Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates
Via ACCESSWIRE
Ainos Reports Second Quarter 2022 Financial Results
Via ACCESSWIRE
Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split
Via ACCESSWIRE
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.